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Abstract
Background: The peptide hormone gastrin exerts a growth-promoting effect in both normal and malignant
gastrointestinal tissue. Gastrin mediates its effect via the cholecystokinin 2 receptor (CCKBR/CCK2R). Although a substantial
part of the gastric adenocarcinomas express gastrin and CCKBR, the role of gastrin in tumor development is not completely
understood. Autophagy has been implicated in mechanisms governing cytoprotection, tumor growth, and contributes to
chemoresistance. This study explores the role of autophagy in response to gastrin in gastric adenocarcinoma cell lines.
Methods: Immunoblotting, survival assays and the xCELLigence system were used to study gastrin induced autophagy.
Chemical inhibitors of autophagy were utilized to assess the role of this process in the regulation of cellular responses
induced by gastrin. Further, knockdown studies using siRNA and immunoblotting were performed to explore the signaling
pathways that activate autophagy in response to gastrin treatment.
Results: We demonstrate that gastrin increases the expression of the autophagy markers MAP1LC3B-II and SQSTM1 in
gastric adenocarcinoma cells. Gastrin induces autophagy via activation of the STK11-PRKAA2-ULK1 and that this signaling
pathway is involved in increased migration and cell survival. Furthermore, gastrin mediated increase in survival of cells
treated with cisplatin is partially dependent on induced autophagy.
Conclusion: This study reveals a novel role of gastrin in the regulation of autophagy. It also opens up new avenues in the
treatment of gastric cancer by targeting CCKBR mediated signaling and/or autophagy in combination with conventional
cytostatic drugs.
Keywords: Gastrin, Gastric adenocarcinoma, Autophagy, STK11-PRKAA2-ULK1 signaling cascade, Cell migration, Cell survival,
Chemoresistance
Background
Autophagy is an evolutionarily conserved process wherein
the cytoplasmic components are degraded to provide cells
with energy during starvation. Basal autophagy is necessary
to maintain homeostasis and can be induced in response
to cellular stress [1, 2]. The process of macroautophagy
(herein referred to as autophagy) involves the engulfment
of cytoplasmic material into de novo generated double
membrane vesicle called autophagosomes. The isolated
material is degraded after the fusion with the lysosomes
[3]. The process of autophagy is orchestrated by a set of
AuTophaGy-related genes (ATGs) that were first identified
in yeast, but later shown to have orthologs in mammals
[4]. Microtubule-associated protein 1 light chain 3 beta
(MAP1LC3B-I/II/ LC3B) is lipidated when autophagy is
induced and plays an essential role in the autophagosome
formation [5]. Sequestosome 1 (SQSTM1/p62) facilitates
the degradation of polyubiquitinated substrates by au-
tophagy via the direct interaction with ubiquitinated
proteins and MAP1LC3B located on the autophagoso-
mal membrane [6]. MAP1LC3B and SQSTM1 are both
produced and degraded in a coordinated manner dur-
ing autophagy and therefore, are used as markers to
study this process [7, 8].
The initiation of autophagy is orchestrated by the
activity of the ULK1 (ATG1) kinase complex [9]. The
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activity of the ULK1 complex is positively regulated by
the adenosine monophosphate-activated protein kinase
(PRKAA2/AMPK) and inhibited by mammalian target
to rapamycin (mTOR). This leads to balancing of cellu-
lar catabolic routes according to the innate needs of the
cell. The activity of the ULK1 complex can be monitored
by using specific antibodies,that recognize the phosphor-
ylation of ULK1 on Ser 555 or Ser 317 (stimulate the ac-
tivity) or on ULK1 Ser 757 (inhibit the activity) [10–12].
The peptide hormone gastrin (G-17) is the central
regulator in the maintenance and organization of the
gastric mucosa and plays a pivotal role in gastric acid
secretion in the stomach [13]. In addition, gastrin exerts
growth-promoting effects in both normal and malignant
gastrointestinal tissues in the oxyntic mucosa and the
gastric epithelial cells [14]. Gastrin has been found to
stimulate proliferation of cancer cell lines isolated from
the stomach, pancreas and colon [15–17]. It has been
reported to promote cellular responses such as migra-
tion, invasion and survival [18–20]. However, the role
of gastrin in the progression of gastric adenocarcinoma
is not completely understood. Nonetheless, hypergastri-
nemia in combination with H. pylori infections are con-
sidered to be a risk factor for the development of
gastric adenocarcinomas [21].
We have previously reported that gastrin treatment of
the pancreatic adenocarcinoma cell line AR42J resulted in
differentially expressed genes which were annotated to
cellular responses such as unfolded protein response
(UPR)/ER stress and survival [22]. It is well established
that UPR/ER stress is counteracted by increased autoph-
agy [23]. Thus, we hypothesized that gastrin may be
involved in the activation of autophagy in human gastric
cancer cells. In this study, we find that gastrin treatment
induces autophagy in the gastric adenocarcinoma cell lines
AGS-Gr and MNK45, concomitant with the activation of
the STK11-PRKAA2-ULK1 signaling cascade. Further, we
demonstrate that gastrin treatment reduces the cytotoxic
effect exerted by cisplatin. We propose that gastrin
induced autophagy is in part responsible for the increased
migration and chemoresistance of the AGS-Gr cells.
Methods
Cells
AGS (human gastric adenocarcinoma, ATCC, Rockville,
MD) and AGS-Gr (stably transfected with CCKBR, gift
from Prof. Andrea Varro, University of Liverpool) cells
were grown in HAM’S F12 (GIBCO, 21765–029) supple-
mented with 10% FCS (GIBCO, 10270–106), 10 μg/ml
penicillin-streptomycin and 2 μg/ml puromycin (GIBCO
A11138-03). The MKN45 (human gastric adenocarcinoma)
cell line was a gift from Prof. Susan A. Watson, University
of Nottingham. The cells were grown in DMEM (GIBCO,
41965–039) with 4.5 g/l glucose, 10% FCS, 10 U/ml
penicillin-streptomycin, and 1 μg/ml fungizone.
Antibodies and siRNAs
The following antibodies were used for immunoblot ana-
lyses in the indicated final dilution: CCKBR (1:300),
(Bioworld Technology, Cat no: BS3159); CCKBR (1:200)
Abbiotech (Catno: 250659), MAP1LC3A-II (1:1000),
(Cell signaling, Cat no:#3868); SQSTM1 (1:1000), (PRO-
GEN Biotechnik GmbH,Cat no: GP62-C); ULK1 (1:500),
(Cat no:#8054); p-ULK1Ser317 (1:500), (Cat no:#6887);
p-ULK1Ser555 (1:500), (Cat no:#5869); p-ULK1 Ser757
(1:500), (Cat no:#6888) PRKAA2α (1:1000), (Cat no:#2
532), p-PRKAA2α Thr172 (1:1000), (Cat no:#2535);
STK11 (1:1000), (Cat no: #3482) p-RAPTOR Ser792
(1:800), (Cat no: #2083), RAPTOR (1:800), (Cat no:
#2280) and p-STK11Ser 428 (1:1000), (Cat no:#3482),
were all obtained from Cell Signaling; ACTA1 (1:5000),
(Abcam, Cat no:8227); GAPDH (1:5000), (Abcam, Cat
no:9484), PCNA (1:2000),(Abcam, Cat no:Ab29) and
HRP-conjugated (1:5000) rabbit & mouse polyclonal
antibodies, (DAKO E0453 and ISO76), Secondary Anti-
body (LICOR) Donkey anti-guinea pig (1:5000), (Cat no:
P/N 926-32411), Goat anti-mouse (1:15000), (Cat no: P/
N 925–32213); Goat anti-rabbit (1:5000), (Cat no: P/N
925–68070). The following siRNAs were used: siRNAs
targeting CCKBR were obtained from (Invitrogen,
Primer no: 250273C09, 250273C10 & 250273C011),
siRNA STK11 (Thermo Scientific Cat no: S02349811) and
ON-TARGET plus Non-Targeting Pool were obtained
from (Dharmacon Cat no: D-001810-01-20). Gastrin
(Sigma Cat no: SCP01050, G-17), Compound C (Millipore
Cat no: 171260), Bafilomycin A1 (Sigma Cat no: B1 793),
the CCKBR antagonist YM022 (Sigma Cat no: SML0220)
and hydroxychloroquine (Sigma Cat no: HO915).
Immunoblot analyses
Cells were cultivated without serum only during gastrin
stimulation and harvested in 8 M Urea lysis buffer,
0.50% Triton-X 100, 0.1 M DTT, Protease inhibitor 1 &
2 Sigma Cat no: P8340) and Phosphatase inhibitors
(Roche). Phosphorylated proteins were harvested in 1 M
Tris–HCl, pH 8.0, 1 M KCl, 0.5 M EDTA, 87% Glycerol,
100% NP-40. A saturation curve for the proteins was
estimated by loading 10–80 μg of protein for immuno-
blotting. We loaded 35 μg of total cell lysate protein to
avoid saturation and assessed ACTA1, MAP1LC3B and
SQSTM1 levels in the linear protein detection range.
The immunoblotting procedure was performed as previ-
ously described [24]. Secondary antibodies were visual-
ized by using the Super Signal West Femto Maximum
Sensitivity Substrate (Pierce, ThermoScientific, Cat no:
#34096). Both fluorescence and chemiluminescence was
visualized using ODYSSEY® Fc Imaging System. Image
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Studio software was used to quantify and adjust contrast
on the immunoblots.
Confocal microscopy
Cells (10 000 cells in 200 μl medium with 10% FBS)
were seeded on Lab-Tek™ chambered coverglass with 8
wells (NUNC, Thermo Scientific) and left overnight.
Cells were serum starved and treated with gastrin (10
nM) and Baf A1 (100 nM) for 4 h. Cells were fixed (4%
paraformaldehyde in PBS) for 10 min, washed (PBS x 2)
and permeabilized (ice-cold MeOH) for 10 min on ice
and washed (PBS x 2). Cells were stained with Draq-5
(1:1000), (Biostatus, DR05500) for 7 min, washed and
stored at 4 °C over night before confocal microscopy.
The cells were immunostained after a 1 h blocking using
3% goat serum in PBS followed by incubation of the
properly diluted primary antibodies in 1% goat serum in
PBS. Unbound antibodies were removed by washing 5
times 5 min incubations in PBS before fluorescent dye
labelled secondary antibodies were applied according to
the species origin of the primary antibody. Confocal mi-
croscopy studies were performed with a Zeiss Axiovert
100-M inverted microscope equipped with an LSM 510
laser-scanning unit and a 1.4 numerical aperture × 63
Plan-Apochromat oil immersion objective. Laser power
was typically 30% and the pinhole was set to 0.8–1.2 μm.
Multitracking was used for dual color imaging at
488 nm and 647 nm.
Transfection
300 000 cells were seeded into 6-well plates and cultured
for 24 h before transfection with siRNA using Metafec-
tene Pro (Biontex Cat no: T040-1.0). The media was
replaced 6 h after transfection. 81 nM siRNA and 12 ul
Metafectene was used per well. The cells were left undis-
turbed for 48 h post transfection. AGS-Gr and MKN45
cells were transfected twice with siRNA targeting
CCKBR on following days to obtain a better knockdown.
Cell viability and proliferation assays
To measure changes in cell viability, gastrin and BafA1
treated - cells were stained using the Apotest FITC kit
(Nexins Research Cat no: N1470036). The cells were
incubated with annexin V FITC (0.2 l g/mL in 19
annexin binding buffer) for 1 h on ice. Propidium iodide
(PI) (1.4 g/mL) was added 5 min prior to data acquisi-
tion using an LSRII flow cytometer (BD Biosciences).
Cells negative for both annexin V and PI staining were
considered viable. The number of metabolic active,
viable cells were quantified using XTT assay by using
TACS XTT cell proliferation assay kit (Trevigen Cat no:
481-025-k) according to manufactures instructions. The
cells were stimulated with gastrin (10 nM) for 2 h,
before cisplatin was added. Hydroxy-chloroquine (HCQ)
was used at a final concentration of 10 μM. The viable
cells were assessed at 48 h after cisplatin treatment.
Autophagy was blocked for 12 h. The ULK1 inhibitor
SBI-0206965 was used with 5 μM final concentration
and added to cells alone or together with gastrin for
24 h and 48 h before absorbance was determined using
a microplate Reader (BIORAD) at dual wavelength;
490 nm and 620 nm.
Migration assay
The xCELLigence® DP system (Roche Diagnostics GmbH,
Germany) was used to study migration as previously
described [25]. Briefly, AGS-Gr cells were seeded into (5.0
x 104 cells/well) the CIM-Plate 16 (Roche). The lower
chamber contained 1 nM gastrin alone or in combination
with ULK1 inhibitor SBI-0206965 (10 μM) final concen-
tration) (Apex Biosciences A8715), Compound C (Milli-
pore), HCQ (20 μM), BafA1 (100nM). Cell migration was
monitored every 15 min on a RTCA DP instrument for
24 h. Data analysis was carried out using RTCA Software
1.2 supplied with the instrument.
Caspase assay
Caspase activity was measured by using the Caspase-Glo
3/7 assayfrom Promega (Madison, WI) according to the
manufacturer’s descriptions. Luminescence was measured
using Wallac 1420 Victor3 plate reader (Perkin Elmer).
The AGS-Gr cells were seeded out into white-walled 96-
well plates (Perkin Elmer) and the cells were treated with
Gastrin (10 nM), cisplatin (10 μM) for 72 h. BafA1 (100
nM) was added 16 h prior to termination of the assay.
Statistics
Statistical values were expressed as mean ± standard
deviation (SD). Statistical analysis was performed by the
two-tailed Student T-test. P values < 0.05 was considered
statistically significant and is labelled with P- values:
*** ≤ 0.01 ** ≤ 0.02, * ≤ 0.05.
Results
Gastrin induces autophagy in gastric adenocarcinoma
cells
Our transcriptome analysis of differentially expressed genes
in the pancreatic adenocarcinoma AR42J cells revealed that
gastrin upregulates the mRNA level of autophagy related
genes (e.g. Sqstm1 and beclin 1 (E-MTAB-1268 and
GSE32869)) [22], suggesting that gastrin may induce
autophagy. Several recent studies have identified elevated
autophagy in gastric cancer [26, 27]. Thus, we tested if
gastrin could induce autophagy and if this could contribute
to tumor progression. We utilized two gastric cancer cell
lines, MKN45 that expresses the CCKBR endogenously
and the AGS-Gr that stably overexpresses the CCKBR
(Additional file 1: Figure S1) [28, 29]. The two cell lines
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were treated with 10 nM gastrin and the protein levels of
MAP1LC3B-II and SQSTM1 were assessed by immuno-
blotting. In both the cell lines, gastrin enhanced the protein
level of MAP1LC3B-II and SQSTM1 in a time dependent
manner (Fig. 1a & b). The protein level of autophagy
related protein ATG5 was also slightly elevated after
gastrin treatment in AGS-Gr and MNK45 cells at 4 h and
2 h, respectively (Fig. 1c & d). Since MAP1LC3B-II and
SQSTM1 are constantly degraded by autophagy, an
increased level of the proteins could result both from
elevated synthesis and/or reduced autophagic degradation.
To discriminate between these two possibilities, gastrin
treatment was performed in the presence of the lysososmal
inhibitor Bafilomycin A1 (BafA1). As expected, treatment
Fig. 1 Gastrin upregulates autophagy markers in gastric adenocarcinoma cells. a and b AGS-Gr and MKN45 cells treated with gastrin (10 nM) for 2–16 h.
The expression of MAP1LC3B-I/II and SQSTM1 is shown by immunoblotting. The images represent one of two independent experiments (c and d) Cells
treated with gastrin for 4 h. The expression of ATG5 is shown by immunoblotting. e and f AGS-Gr and MKN45 cells treated with BafA1 (100 nM) and gastrin
for 8 h and 4 h, respectively. The expression of MAP1LC3B-II and SQSTM1 is shown by immunoblotting. The images represent one of three independent
experiments. Graphs represents three independent experiments, mean +/− SEM (P- values: **≤ 0.02 and *≤ 0.05) (g) AGS-Gr cells treated with BafA1 and
gastrin for 4 h. Cells were stained for MAP1LC3B (Alexa 488) and SQSTM1 (Alexa 647). The images were processed using IMAGE J software. 300 cells were
manually counted for SQSTM1 puncatated structures in the cytosol. U.S. = untreated cells. The images represent one of three independent experiments.
Graphs represent three independent experiments; mean +/− SEM (P- value: ***≤ 0.02)
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of cells with BafA1 alone caused an accumulation of the
MAP1LC3B and SQSTM1 proteins (Fig. 1e & f). Interest-
ingly, in the AGS-Gr cells treated with gastrin + BafA1, we
found a significant increase in MAP1LC3B-II and
SQSTM1 levels compared to the level in cells treated with
BafA1 alone (Fig. 1e; Additional file 1: Figure S2 (a) & (b)).
In the MKN45 cells, gastrin + BafA1 treatment caused a
small but consistent enhancement in the level of
MAP1LC3B-II, while the effect on SQSTM1 was not
statistically significant (Fig. 1f). The stronger gastrin
response demonstrated in the AGS-Gr cells might be
attributed to the higher expression of the CCKBR in these
cells (Additional file 1: Figure S1).
To substantiate the above findings, we examined the
cellular localization of SQSTM1 and MAP1LC3B-II
using immunostaining. In AGS-Gr cells, we found a
Fig. 2 Gastrin induced autophagy is mediated via the CCKBR: (a and b) AGS-Gr and MKN45 pretreated overnight with YM022 (100 nM) before treatment
with BafA1 and gastrin for 4 h. The expression of MAP1LC3B-II and SQSTM1 is shown by immunoblots representing one of three independent experiments.
(c) MKN45 cells transfected with siRNA CCKBR. Protein expression of CCKBR was analyzed by immunoblotting. (d) MKN45 cells transfected with siRNA
CCKBR and treated with BafA1 and gastrin. MAP1LC3B-II and SQSTM1 expression is shown by immunoblotting. The image represents one of three
independent experiments. Bar graphs (a, b, c and d) show mean +/− SEM, (n= 3, P- value **≤ 0.02 and *≤ 0.05)
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significant increase in the number of cytoplasmic
SQSTM1-stained punctuated structures 4 h after gastrin
treatment (Fig.1g & Additional file 1: Figure S3). In line
with the immunoblotting analyses, the number of
SQSTM1 structures were higher when combined with
the lysosomal inhibitor and gastrin compared to each
treatment alone.
The activity of CCKBR can be targeted by using the
chemical inhibitor YM022 [30]. In line with a role of gastrin
in inducing autophagy, pretreatment with YM022 resulted
in a decrease in the gastrin induced MAP1LC3B-II level by
approximately 50% and 35% in AGS-Gr and MKN45 cells,
respectively (Fig. 2a & b; compare gastrin + BafA1 treated
cells +/− YM022). Consistently, the presence of YM022
reduced gastrin induction of SQSTM1 protein by 45% and
30% in the AGS-Gr and MKN45 cells, respectively. Like-
wise, the knockdown of CCKBR in MKN45 cells using
siRNA (Fig. 2c) significantly reduced gastrin induced au-
tophagy (i.e. downregulation of SQSTM1 and MAP1LC3B-
II levels) (Fig. 2d). Collectively, the data demonstrates that
the gastric adenocarcinoma cell lines display an increased
autophagy in response to gastrin in a CCKBR dependent
manner.
Blocking of autophagy reduces gastrin-induced
migration
Others and we have previously reported increased mi-
gration and cell survival in response to gastrin [18, 24, 31].
In the present study, we assessed the influence of gastrin
induced autophagy on both cell migration and cell
survival. Autophagy has an established role in cell survival
[32]. Recently it was also identified as an important factor
in the regulation of migration of Ras transformed
MCF10A cells [33]. Thus, we tested if autophagy contrib-
utes to the gastrin induced migration. Inhibiting lysosomal
Fig. 3 Gastrin induced migration is dependent on autophagy. (a) AGS-Gr cells treated with gastrin (1 nM), BafA1 (100 nM) and YM022 (50 nM).
Migration was monitored real-time for 24 h using xCELLigence technology. Untreated (blue), gastrin (green), YM022 (pink), gastrin + YM022
(violet), BafA1 (red), gastrin + BafA1 (light blue). Graphs represent of one of three independent experiments. (b) AGS-Gr cells treated with gas-
trin, YM022 and HCQ (20 μM)). Untreated (violet), Gastrin (light blue), HCQ (pink), HCQ+ gastrin (dark blue), HCQ+ YM022 (green), HCQ+ YM022 + gas-
trin (red). (c) Gastrin induced migration is dependent on ULK1. AGS-Gr cells were treated with gastrin and ULK1 inhibitor SBI-026965 (SBI) (10 μM) Untreated
(red), gastrin (green), SBI-026965 (blue), gastrin + SBI-026965 (pink). (a, b and c) Graphs represent of one of three independent experiments. Bar graphs repre-
sent mean +/− SEM (n= 3, P-value*: ≤ 0.05, **≤ 0.01, ***≤ 0.001)
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degradation in the AGS-Gr cells with BafA1 or hydro-
chloroquinone (HCQ) significantly reduced gastrin-
induced migration by approx. 60% (BafA1) and 40%
(HCQ) at 18 h (Fig. 3a & b). When the CCKBR antagonist
YM022 was added to the cells, we found that gastrin
induced migration was inhibited (Fig. 3a). The antagonist
by itself did not influence migration. Further, YM022 was
utilized in combination with HCQ and gastrin, we show
that the migration was further reduced significantly
(30%) (Fig. 3b; compare HCQ + gastrin versus HCQ +
gastrin + YM022).
The ULK1 inhibitor SBI-026965 was used to evaluate
the role of autophagy in induced migration. We find that
inhibition of ULK1 (ATG1) resulted in a reduction of
gastrin induced migration by 50% (18 h) compared to
untreated cells (Fig. 3c). Taken together, our results
suggest that autophagy plays a crucial role in gastrin
induced migration in the AGS-Gr cells.
Blocking of autophagy reduces gastrin-induced
cell survival
Induced autophagy represents a survival mechanism in
tumour cells that may enable them to survive during
stressful conditions including exposure to cytostatic
drugs [27]. We examined whether gastrin induced
autophagy was essential for the increased cell survival.
Fig. 4 Gastrin induced survival is dependent on autophagy. (a) AGS-Gr cells treated with gastrin +/− BafA1 for 18 h. Cell viability was assessed using
annexin V-PI staining and flow cytometric analyses. The viability of untreated cells (U.S.) is set to 1.0. (b) Gastrin reduces cisplatin induced cell death.
AGS-Gr cells treated with increasing doses of cisplatin (7.5-90 μM) in presence or absence of gastrin (10 nM). Cell viability assessed by XTT assay; the
viability of cisplatin treated cells is set to 1.0 for each concentration (c) AGS-Gr cells treated with gastrin (2 h) with subsequently treatment with cisplatin
(7.5 μM) for 36 h. Autophagy was blocked for 12 h using HCQ. Cell viability was determined by XTT assay; the viability of untreated cells (U.S.) set to
1.0. (d) Cells treated with gastrin for (2 h) and subsequently with increasing concentrations of cisplatin (1–7.5 μM) for 36 h before autophagy was
blocked for 12 h. (e) Gastrin induced survival is dependent on ULK1. AGS-Gr cells treated with ULK1 inhibitor SBI-026965 (SBI) (5 μM) for
24 h and 48 h in the presence or absence of gastrin (10 nM). (f) Caspase activity performed with AGS-Gr cells pretreated with gastrin (2 h),
followed by cisplatin (10 μM) treatment for 72 h. Autophagy was blocked for 12 h with BafA1. Bar graphs (a, b c, d, e and f) represent SEM
(n = 3, P-value: * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001)
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Consistent with previous reports, gastrin caused a slight,
but consistent and significant increase in the number of
viable cells under serum-free conditions using annexin-
PI staining (Fig. 4a). The lysosomal inhibitor BafA1 did
not affect the viability of AGS-Gr cells by itself, but
interestingly, adding BafA1 together with gastrin
reduced the pro-survival effect of gastrin by 30% (Fig. 4a
& Additional file 1: Figure S4a). The data suggests that
induced autophagy contributes to enhanced cell survival
in response to gastrin.
Cisplatin is used in the treatment of gastric adenocar-
cinomas [34, 35], and we tested whether gastrin induced
autophagy could modify the cellular response to cisplatin
in vitro. Initially, AGS-Gr cells were treated with
increasing concentrations of cisplatin (1–90 μM) in the
presence and absence of gastrin for 24 h, 48 h and 72 h.
The numbers of surviving cells were determined by their
metabolic activity (XTT assay). We found that gastrin
treatment reduced the sensitivity towards cisplatin
(Fig. 4b & Additional file 1: Figure S4 (c) & (d)). To
explore if this gastrin induced survival was due to the
induced autophagy, we performed the experiments in
the presence of the autophagy inhibitor HCQ. Interest-
ingly, addition of HCQ reduced the survival effect of
gastrin (Fig. 4c) and the viability of cells treated with
gastrin + cisplatin (Fig. 4d). HCQ diminished the survival
effect induced by gastrin with increasing concentrations
(1 μM, 4 μM and 7.5 μM) of cisplatin (Fig. 4d). This
indicates that the survival effect of gastrin involves the
induction of autophagy. Notably, HCQ did not affect
cell viability by itself (Fig. 4c). As anticipated, HCQ
treated cells showed an accumulation of both SQSTM1
and MAP1LC3B-II (Additional file 1: Figure S4 (e)).
Next, we treated AGS-Gr cells with the ULK1 inhibitor
SBI in the presence of BafA1 + gastrin. This resulted in
reduced accumulation of SQSTM1 and MAP1LC3B-II
(Additional file 1: Fig. S4 (f )). Further, AGS-Gr cells
were treated with gastrin +/− SBI and cell viability
determined by XTT assay. Consistently, gastrin alone
increased the cell viability, but in the presence of SBI,
cell viability was reduced by approx. 15% compared to
cells treated with gastrin alone, at both 24 and 48 h
(Fig. 4e). As previously reported the inhibitor on its
own reduced cell viability [36].
To establish the link between gastrin induced autophagy
and apoptosis, we examined the activation of caspase 3/7
in the AGS-Gr cells. Initially, the cells were treated with
gastrin +/− BafA1. Gastrin treatment alone reduced the
induction of caspase 3/7 activity (Fig. 4f), this coincides
with a study in the gastrin responsive AR42J cells [37].
The reduced activation of caspases in the presence of gas-
trin was counter acted by BafA1 treatment (Fig. 4f).
When, the cells were treated with gastrin in the presence
or absence of cisplatin (autophagy blocked 16 h), we find
that the inhibition of autophagy increased the activation
of caspase 3/7 (Cisplatin + gastrin + BafA1 versus Cis-
platin + gastrin) (Fig.4f). However, activation of caspases
in the presence of cisplatin alone or in combination with
BafA1 was found not to be significant. Further, when gas-
trin was added to cells treated with cisplatin, we observed
a reduced caspase activity, suggesting that gastrin exerts a
cytoprotective effect on these cells (Fig. 4f). Collectively,
these results suggest that gastrin induced autophagy is
linked to the anti-apoptotic effect exerted by gastrin.
Gastrin activates the STK11–PRKAA2-ULK1
signaling pathway
The data presented above are consistent with a gastrin
induced autophagy that stimulates migration and potenti-
ates cell survival. The ULK1 kinase is the master regulator
of autophagy by coordinating the initial steps of autopha-
gosome formation. Since the data suggests that gastrin
induces autophagy, we asked if this involves the activation
of ULK1. We have recently demonstrated that gastrin
induces STK11 Ser 428 phosphorylation in AGS-Gr and
MKN45 cells [25], indicating that the STK11-PRKAA2-
ULK1 signalling pathway might be involved in gastrin
mediated induction of autophagy. Thus, we treated cells
with gastrin and examined the phosphorylation of
PRKAA2 by immunoblotting. In line with a gastrin
induced activation of STK11, the phosphorylation of the
STK11 targeted site in PRKAA2 (Thr 172) was transiently
elevated in both AGS-Gr and MKN45 cells (Fig. 5a & b).
Concurrent with an elevated activity of PRKAA2, we
found that gastrin treatment also increased the phosphor-
ylation of the autophagy activating sites of the ULK1 com-
plex (Ser 317 and Ser 555) (Fig 5a & c). These data
indicate a direct signalling pathway mediated by gastrin/
CCKBR to the activation of ULK1 via increased activity of
STK11 and PRKAA2. However, ULK1 may in addition be
regulated indirectly by the same pathway, ie. if the gastrin
induced PRKAA2 activity results in reduced mTOR activ-
ity. To further unravel signalling pathways involved in au-
tophagy, we examined gastrin mediated phosphorylation
of Regulatory-associated protein of mTOR (Raptor) Ser
792, which is known to inhibit mTOR activity. As shown
in (Fig 5a & b), gastrin induced the phosphorylation of
Raptor Ser 792. In the AGS-Gr cells, the phosphorylation
of Raptor Ser 792 appeared as early as 5 min, and in the
MKN45 cells at 15 min. Consistent with the activation of
ULK1 on the autophagy activating sites (Ser 555 and Ser
317) we also found that the mTOR substrate 4EBP1 was
less phosphorylated after gastrin treatment of the AGS-Gr
cells (Fig. 5d). Collectively, these results suggest that the
elevated autophagy in response to gastrin treatment is
both due to a direct effect on PRKAA2, which induces the
ULK1 activity, and the indirect effect via reduced mTOR
activity. Additionally, AGS-Gr cells were transfected with
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siRNA towards STK11 and subsequently treated with gas-
trin before the assessment of the autophagy markers. The
protein level of STK11 was reduced by ~ 60% compared
to cells transfected with non-targeting siRNA (Fig. 6a). As
shown in Fig. 6b, we observed a reduction in gastrin
induced expression of MAP1LC3B-II and SQSTM1 when
STK11 was knocked down. Similarly, targeting
PRKAA2 with siRNA or a chemical inhibitor (Comp C)
resulted in the downregulation of SQSTM1 (Fig. 6c, d
& Additional file 1: Figure S5). Taken together, our
results are congruent with a gastrin induced autophagy
involving the activation of STK11–PRKAA2-ULK1
signaling pathway.
To elucidate a functional relationship between the
gastrin-induced signalling cascades detailed above and
migration, we treated AGS-Gr cells with the PRKAA2
inhibitor Compound C (Comp C). We found that Comp
C decreased the gastrin-induced migration by approx.
40% (18 h) (Fig. 6e), indicating the involvement of the
autophagy regulated signalling pathway. Together, these
results suggest that the STK11 - PRKAA2 pathway
controls autophagy and that this is important for the
enhanced cell survival and migration in response to
gastrin.
Discussion
Gastrin exerts a growth promoting effect on several
gastrointestinal cancer cells and a variety of neoplasms
that express CCKBR, including neuroendocrine, pancre-
atic, medulla thyroid and lung cancer [38–40]. Interest-
ingly, Hur et al. demonstrated that gastrin and CCKBR
are expressed in approx. 50% of gastric carcinoma
tissues, and patients with diffuse type of gastric carcin-
oma expressing both gastrin and CCKBR had poorer
prognosis compared to those who were negative for both
[41]. However, the role of gastrin in adenocarcinoma is
Fig. 5 Gastrin induces phosphorylation of the LKB-1-PRKAA2-ULK1 pathway. (a, b and c) Cells were serum starved overnight and treated with
gastrin (10 nM). Phosphorylated STK11 (Ser 428), PRKAA2 (Thr 172), ULK1 (Ser 317 & Ser 555), Raptor (Ser 792) and 4EBP1 (Thr 37/46) are shown
by immunoblotting. Data was normalised to total protein and immunoblots shown represent one of three independent experiments. Bar
graphs (c) represent SEM (n = 3, P-value: *** ≤ 0.01)
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still not completely understood, and whether gastrin acts
as an autocrine/paracrine growth factor in gastric carcin-
oma is unclear. In the current study, we report that
gastrin induces autophagy and increases cell migration
and survival in vitro, and suggest that these molecular
mechanisms may contribute to tumor progression of
gastric cancer cells.
Several recent studies have indicated a role of autoph-
agy and autophagy related proteins in the progression of
gastric cancer [42, 43]. Immunohistochemistry analysis
Fig. 6 Knockdown of STK11 and PRKAA2 downregulates gastrin mediated autophagy. (a) Knockdown of STK11 in AGS-Gr cells. (b) AGS-Gr
cells transfected with siRNA STK11 for 48 h before BafA1 and gastrin treatment (4 h). Expression of SQSTM1 and MAP1LC3B-II are shown
by immunoblotting representing one of four independent experiments. Bar graphs (a and b) show mean +/− SEM (n = 3, P- value ** ≤
0.02 and * ≤ 0.05). (c) Knockdown of PRKAA2 in AGS-Gr cells. (d) AGS-Gr cells transfected with siRNA PRKAA2 and treated with BafA1 and
gastrin (4 h). Expression of PRKAA2 and SQSTM1 is shown by immunoblotting representing one of three independent experiments. (e)
Gastrin induced migration is dependent on PRKAA2. AGS-Gr cells treated with gastrin (1 nM) and PRKAA2 inhibitor Compound C (10 μM)
for 24 h. Migration was monitored using xCELLigence technology. Untreated (red), Comp C (blue), gastrin + Comp C (pink), gastrin (green).
Bar graphs (a, b, c, d and e) show mean +/− SEM (n = 3, P-value*: ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001)
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has identified an elevated staining intensity for autoph-
agy related proteins such as Beclin1, Atg5, Atg8/
MAP1LC3B, and SQSTM1/p62 in gastric cancer tissue
[26, 42]. Upregulation of MAP1LC3A was shown to
correlate with an increase in Ki67 positive cells in
gastrointestinal tumors [44]. Ge et al. demonstrated that
ATG5 was highly expressed in gastric cancer patients
compared to healthy individuals, which was speculated
to contribute to increased chemoresistance [45].
Autophagy is an incessant process, where numerous
proteins including MAP1LC3B and SQSTM1 are con-
stantly degraded. Thus, elevated levels of the proteins in
a biopsy could result from both activation and inactiva-
tion of the process. Additionally, how autophagy could
possibly be activated and contribute to gastric cancer de-
velopment is currently not fully understood. We find
that the peptide hormone gastrin induces autophagy in
two gastric adenocarcinoma cell lines via the STK11-
PRKAA2-ULK1 pathway. This signaling pathway may
contribute to cancer development by both increasing cell
survival and cell migration.
Loss of STK11 has been shown to correlate with in-
creased cancer development. Nguyen and Liu et al. [46, 47]
demonstrated that STK11 deficient melanoma cells have
increased invasive properties compared to cells with nor-
mal amounts of STK11 protein. Contrarily, STK11 has
been reported to be necessary for the survival of colorectal
cancer cells, hepatocyte proliferation, liver regeneration
and cell survival of liver tumors with constitutive activation
of AKT [48, 49]. Our result establishes a functional role of
STK11 in gastrin induced autophagy; the inhibition of
downstream kinases PRKAA2 and ULK1 reduced gastrin-
induced migration and survival. The role of autophagy in
the migration of cancer cells is currently being investigated.
Kenefic et al. found that autophagy is involved in the turn-
over of focal adhesion (FA), promoting FA disassembly and
that this is dependent upon the autophagic receptor NBR1
[33]. Further, activation of autophagy in glioblastoma cells
impairs the migration and invasion capacities via the
downregulation of epithelial mesenchymal transition pro-
teins such as SNAIL and SLUG [50]. Autophagy deficiency
was found to increase SQSTM1/p62 levels, resulting in re-
duced E-cadherin expression, stabilization of the oncogenic
protein Twist1 and promotion of cell migration, invasion
and proliferation of human squamous cell carcinomas [51].
Gastrin is known to induce cell survival via several
mechanisms [18, 52]. We find that gastrin partially
counteracts the apoptotic effect of cisplatin, and block-
ing autophagy reduces the survival effect induced by
gastrin. Xu et al. reported targeting autophagy sensitizes
gastric cancer cells to oxaliplatin induced apoptosis [32].
Inhibiting lysosomal degradation by using BafA1 in com-
bination with 5-Flurouracil (5-FU) resulted in decreased
viability and colony forming capacity of SGC-7901 cells
[27]. Kim et al. showed that cisplatin treatment induced
phosphorylation of AMPK in the AGS cells, and that
pharmacological inhibition/siRNA towards AMPK sensi-
tized the cells to cisplatin induced apoptosis [53]. These
results suggest that AMPK and autophagy contribute to
a general chemo resistance and act in a cytoprotective
manner in response to anti-cancer therapy.
Recently Egan et al., found that inhibition of ULK1
reduced the survival of A549 cells significantly, when
combined with a mTOR inhibitior [36]. In our study,
we report that the ULK1 inhibitor SBI, downregulates
gastrin induced autophagy as well as reduces the
associated migration and survival. We suggest that
increased autophagic flux may be one of the several
mechanisms by which gastrin induces migration, cell
survival and chemoresistance. Pharmacological inter-
ference of ULK1 and PRKAA2 as therapeutic targets
might provide a novel therapeutic strategy to target
gastric cancer cells, which are resistant to cisplatin/5-
FU treatment. In fact, the combination of HCQ with
several chemotherapeutic agents is currently being
investigated in clinical trials [54, 55]. These results lay
the foundation for further investigation of the role of
gastrin induced autophagy in survival and metastasis.
Conclusion
Our data demonstrates that gastrin regulates autophagy
via the STK11-PRKAA2-ULK1 pathway in vitro. We show
that the gastrin induced migration and survival of gastric
adenocarcinoma cells is partially dependent on induced
autophagy. These results may contribute to a better
understanding of the role of gastrin in gastric cancer.
Blocking of autophagy may be a therapeutic approach for
sensitizing gastric cancer cells to chemotherapy.
Additional file
Additional file 1: Figure S1a. Expression of CCKBR in gastric
adenocarcinoma cells. AGS cells have low abundance of the CCKBR,
MKN45 express the CCKBR endogenously and AGS-Gr cells are stably
transfected with the CCKBR. S1b. Negative control images of the MKN45
cells stained for the CCKBR (phase contrast, Alexa 488, Draq5). Figure S2:
Gastrin induces autophagy. AGS-Gr (a & b) cells treated with gastrin (10
nM), BafA1 (100 nM) and gastrin + BafA1 for 2 and 4 h. Protein expression
of MAP1LC3B-II and SQSTM1 was analyzed by immunoblotting. The im-
ages shown represent one of three independent experiments. Graphs
show mean +/- SEM (P- values: *** ≤ 0.01 **≤ 0.02, and * ≤ 0.05). Figure
S3: Negative controls (primary antibodies omitted) for MAP1LC3B (Alexa
488) and SQSTM1 (Alexa 647). Figure S4: Gastrin mediated survival is
dependent on autophagy. (a): A representative cytometric plots showing
AGS-Gr cells treated with BafA1 and gastrin for 18 h. Cell viability was
assessed using annexin V-PI staining and flow cytometric analyses. Block-
ing autophagy reduces gastrin mediated survival in AGS-Gr cells. (b): Cell
viability assessed in AGS-Gr cells treated with gastrin (10 nM) for 6- 72 h.
(c & d): Cells treated with gastrin (2 h) and subsequently treated with in-
creasing concentrations of cisplatin. Viability was assessed at 24 and 72 h. Re-
sults show mean +/-SD (n=3, P-values: * ≤ 0.05 ** ≤ 0.01 *** ≤ 0.001). (e):
AGS-Gr cells treated with HCQ for 8 h. Protein expression of MAP1LC3B-II and
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SQSTM1 was detected by immunoblotting. (f) Gastrin induced autophagy is
dependent on ULK1: AGS-Gr cells treated with gastrin, BafA1 and ULK1 inhibi-
tor SBI-0206965 (10 μM) for 4 h. Protein expression of MAP1LC3B-II and
SQSTM1 was detected by immunoblotting. The immunoblots represent one
of three independent experiments. Figure S5: Inhibition of gastrin induced
autophagy by Comp C. AGS-Gr cells pretreated with Compound C (10 μM) for
12 h before adding BafA1 and gastrin (4 h). Protein expression of SQSTM1 is
shown by immunoblotting. The blot represents one of two independent ex-
periments. (DOCX 2504 kb)
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